Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
EDQM
0
USP
0
JP
0
Others
0
FDA Orange Book
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
API
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
Drugs in Development
Details:
Kadcyla (ado-trastuzumab emtansine) is a HER2-targeted antibody-drug conjugate. It is being evaluated for the treatment of HER2-positive early-stage breast cancer With residual invasive disease after neoadjuvant treatment.
Lead Product(s): Trastuzumab Emtansine
Therapeutic Area: Oncology Brand Name: Kadcyla
Study Phase: Phase IIIProduct Type: Antibody-drug Conjugate
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 12, 2023
Lead Product(s) : Trastuzumab Emtansine
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Genentech’s Kadcyla Is the First Targeted Therapy to Show Significant Overall Survival Benefit i...
Details : Kadcyla (ado-trastuzumab emtansine) is a HER2-targeted antibody-drug conjugate. It is being evaluated for the treatment of HER2-positive early-stage breast cancer With residual invasive disease after neoadjuvant treatment.
Product Name : Kadcyla
Product Type : Antibody-drug Conjugate
Upfront Cash : Inapplicable
August 12, 2023
Details:
Kadcyla (trastuzumab emtansine) is a HER2 modulator, antibody-drug conjugate. It is being evaluated in phase 3 clinical trials for the treatment of HER2-positive early-stage breast cancer.
Lead Product(s): Trastuzumab Emtansine
Therapeutic Area: Oncology Brand Name: Kadcyla
Study Phase: Phase IIIProduct Type: Antibody-drug Conjugate
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 12, 2023
Lead Product(s) : Trastuzumab Emtansine
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Kadcyla (trastuzumab emtansine) is a HER2 modulator, antibody-drug conjugate. It is being evaluated in phase 3 clinical trials for the treatment of HER2-positive early-stage breast cancer.
Product Name : Kadcyla
Product Type : Antibody-drug Conjugate
Upfront Cash : Inapplicable
August 12, 2023
Details:
TUKYSA (tucatinib) is an oral medicine that is a tyrosine kinase inhibitor of the HER2 protein and in combination with ado-trastuzumab emtansine is being developed in patients with HER2-positive metastatic or unresectable breast cancer.
Lead Product(s): Tucatinib,Trastuzumab Emtansine
Therapeutic Area: Oncology Brand Name: Tukysa
Study Phase: Approved FDFProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 12, 2023
Lead Product(s) : Tucatinib,Trastuzumab Emtansine
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
TUKYSA® (tucatinib) in Combination with Antibody-Drug Conjugate ado-Trastuzumab Emtansine Improve...
Details : TUKYSA (tucatinib) is an oral medicine that is a tyrosine kinase inhibitor of the HER2 protein and in combination with ado-trastuzumab emtansine is being developed in patients with HER2-positive metastatic or unresectable breast cancer.
Product Name : Tukysa
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 12, 2023
Details:
Patients already treated with Trastuzumab may still have the disease and would require this therapy as the next step. The high cost of therapy is a barrier to availing this therapy and Ujvira bridges this need.
Lead Product(s): Trastuzumab Emtansine
Therapeutic Area: Oncology Brand Name: Ujvira
Study Phase: Approved FDFProduct Type: Antibody-drug Conjugate
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 24, 2021
Lead Product(s) : Trastuzumab Emtansine
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Zydus Cadila Launches ‘Ujvira’ to Treat Breast Cancer
Details : Patients already treated with Trastuzumab may still have the disease and would require this therapy as the next step. The high cost of therapy is a barrier to availing this therapy and Ujvira bridges this need.
Product Name : Ujvira
Product Type : Antibody-drug Conjugate
Upfront Cash : Inapplicable
May 24, 2021
Details:
Approval is based on the study which evaluated the efficacy and safety of Kadcyla adjuvant therapy in patients with HER2-positive early breast cancer who did not have pathologic complete response following neoadjuvant therapy including Herceptin.
Lead Product(s): Trastuzumab Emtansine
Therapeutic Area: Oncology Brand Name: Kadcyla
Study Phase: Approved FDFProduct Type: Antibody-drug Conjugate
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 21, 2020
Lead Product(s) : Trastuzumab Emtansine
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Approval is based on the study which evaluated the efficacy and safety of Kadcyla adjuvant therapy in patients with HER2-positive early breast cancer who did not have pathologic complete response following neoadjuvant therapy including Herceptin.
Product Name : Kadcyla
Product Type : Antibody-drug Conjugate
Upfront Cash : Inapplicable
August 21, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Europe
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Canada
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
NEWS #PharmaBuzz
Global Sales Information
ABOUT THIS PAGE
